Newron Pharmaceuticals S.p.A. (SWX:NWRN)

Market Cap	138.31M
Revenue (ttm)	48.21M
Net Income (ttm)	14.86M
Shares Out	19.96M
EPS (ttm)	0.80
PE Ratio	8.69
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,388
Average Volume	64,157
Open	6.70
Previous Close	6.93
Day's Range	6.48 - 7.17
52-Week Range	6.10 - 11.20
Beta	0.63
RSI	23.88
Earnings Date	Apr 1, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company’s product pipeline includes Evenamide, an add-on therapy for the treatment of Schiz...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 22
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: NWRN

Financial Performance

Financial numbers in EUR